The announcement by the US Centers for Disease Control and Prevention came yesterday as authorities try to identify people who had contact with a 49-year-old woman in the eastern state of Pennsylvania whose urinary tract infection tested positive for E. Coli bacteria carrying the antibiotic-resistant mcr-1 gene.
Starting in the fall, the CDC will provide infrastructure and lab capacity for "seven to eight regional labs, and labs in all states and seven major cities/territories, to detect and respond to resistant organisms recovered from human samples," the agency said in a statement.
The Pennsylvania woman had not travelled abroad recently and officials do not know how she contracted the bacteria with the antibiotic-resistant gene previously found in China and Europe.
The mcr-1 gene makes bacteria resistant to the drug colistin, which is used as an antibiotic of last resort.
Colistin has been available since 1959 to treat infections but was abandoned for human use in the 1980s due to high kidney toxicity.
However, colistin has been brought back as a treatment of last resort in hospitals and clinics as bacteria have started developing resistance to other, more modern drugs.
The CDC said an investigation has determined that the Pennsylvania patient did not have a type of bacteria known as carbapenem-resistant enterobacteriaceae (CRE) and it was not resistant to all antibiotics.
"The presence of the mcr-1 gene, however, and its ability to share its colistin resistance with other bacteria such as CRE raise the risk that pan-resistant bacteria could develop," the CDC said.
Its discovery in the United States for the first time "heralds the emergence of truly pan-drug resistant bacteria," said a Defense Department report on the finding published last week in Antimicrobial Agents and Chemotherapy, a journal of the American Society for Microbiology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
